Some studies suggested the use of flavonoids as potential therapeutic agents for AD and PD [78], since it has been demonstrated that flavonoids slow down the development of AD-like pathophysiology and related neurodegenerative diseases by disrupting amyloid β protein production, activating α-secretase (ADAM10), and inhibiting β-secretase (BACE-1) [79]. This evidence concerns the gene BACE1 and Alzheimer disease.